Browse studies

Find your next paid study

12 recruiting studies matching your filters

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy

The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment …

Leukemia, Myeloid, Acute

Estimated

~$10 – $8,750

Janssen Research & Development, LLCNCT06852222

Phase 1

Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)

This study is for patients who have a type of blood cancer that expresses the protein CD70, which includes acute myeloid leukemia (AML), T-cell leukemia or B-c…

Leukemia, Myeloid, AcuteLeukemia, B-cellLeukemia, T-Cell

Estimated

~$10 – $6,250

Baylor College of MedicineNCT06345027

Phase 1

Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute m…

AMLAML With Mutated NPM1Hematologic Malignancy+9 more

Estimated

~$10 – $8,750

Kura Oncology, Inc.NCT06001788

Observational

eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation

The goal of this study is to test an electronic health (eHealth) mindfulness-based music therapy intervention to improve health-related quality of life and red…

Stem Cell TransplantationMyelodysplastic SyndromesLeukemia, Myeloid, Acute+2 more

Estimated

~$10 – $6,250

University of MiamiNCT07469592

A Prospective Pilot Study of the Genetic Determinants of Toxicity and Response to Azacitidine and Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia Through Evaluation of Polymorphisms in Pharmacokinetic Genes and Venetoclax Levels

The purpose of this research is to see how certain genetic variations relate to side effects and outcomes experienced while receiving treatment with azacitidin…

Leukemia, Myeloid, Acute

Estimated

~$10 – $750

Wake Forest University Health SciencesNCT06580106

Phase 1

Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD33 Linked to TCRζ And 4-1BB Signaling Domains In Combination With CD33KO-HSPC In Subjects With Refractory Or Relapsed Acute Myeloid Leukemia

The purpose of this study is to provide a new type of treatment for AML. This treatment combines a new type of stem cell transplant along with treatment using …

Leukemia, Myeloid, Acute

Estimated

~$10 – $6,250

University of PennsylvaniaNCT05945849

Phase 2

A Phase 2 Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

This study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopo…

Leukemia, Myeloid, AcuteMyelodysplastic SyndromesMixed Phenotype Acute Leukemia

Estimated

~$10 – $8,750

Orca Biosystems, Inc.NCT07216443

Phase 1

Phase I/II Study of DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

This Phase I/II trial evaluates the safety and preliminary efficacy of DFP-10917 combined with venetoclax in relapsed or refractory acute myeloid leukemia. DFP…

Leukemia, Myeloid, Acute

Estimated

~$10 – $8,750

Delta-Fly Pharma, Inc.NCT06382168

Phase 2

A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Leukemia or Lymphoma

This study will evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in less complications fo…

Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, Acute

Estimated

~$10 – $7,500

Guenther KoehneNCT05565105

Phase 1

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia and Other Selected Hematologic Malignancies, With and Without Mixed Lineage Leukemia (MLL) Rearrangement or Nucleophosmin 1 (NPM1) Mutation (Horizen-1)

A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.

Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, AcuteMultiple Myeloma+1 more

Estimated

~$10 – $8,750

Sumitomo Pharma America, Inc.NCT04988555

Phase 1

A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed …

Leukemia, Myeloid, AcuteRefractory AMLRelapsed Adult AML+2 more

Estimated

~$10 – $8,750

Aptose Biosciences Inc.NCT03850574

Phase 1

A Phase 1/1b Open-Label, Dose Escalation, First-in- Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)

Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myeloge…

LeukemiaLeukemia, MyeloidLeukemia, Myeloid, Acute+3 more

Estimated

~$10 – $8,750

BlossomHill TherapeuticsNCT06501196